MiniMed Group Inc (NASDAQ:MMED) Given Consensus Rating of “Moderate Buy” by Analysts

MiniMed Group Inc (NASDAQ:MMED) has been given a consensus rating of “Moderate Buy” by the fifteen brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and twelve have issued a buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $21.3333.

MMED has been the topic of several research analyst reports. Citigroup initiated coverage on MiniMed Group in a research report on Tuesday, March 31st. They issued a “buy” rating and a $23.00 price objective on the stock. Bank of America cut their price objective on MiniMed Group from $27.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Morgan Stanley initiated coverage on MiniMed Group in a research report on Tuesday, March 31st. They issued an “overweight” rating and a $19.00 price objective on the stock. Wall Street Zen upgraded MiniMed Group to a “hold” rating in a report on Saturday, March 14th. Finally, Benchmark restated a “buy” rating on shares of MiniMed Group in a report on Thursday, June 4th.

MiniMed Group Stock Performance

NASDAQ MMED opened at $15.16 on Friday. The business has a 50 day simple moving average of $12.91. MiniMed Group has a 12 month low of $10.65 and a 12 month high of $20.48.

MiniMed Group (NASDAQ:MMED) last issued its quarterly earnings data on Wednesday, June 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The firm had revenue of $837.00 million during the quarter. The company’s revenue was up 15.6% compared to the same quarter last year.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.